WO2015165833A1 - A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents
A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline Download PDFInfo
- Publication number
- WO2015165833A1 WO2015165833A1 PCT/EP2015/058998 EP2015058998W WO2015165833A1 WO 2015165833 A1 WO2015165833 A1 WO 2015165833A1 EP 2015058998 W EP2015058998 W EP 2015058998W WO 2015165833 A1 WO2015165833 A1 WO 2015165833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- sap
- disease
- formula
- treatment
- Prior art date
Links
- HZLAWYIBLZNRFZ-VXGBXAGGSA-N cphpc Chemical compound OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(O)=O)CCC1 HZLAWYIBLZNRFZ-VXGBXAGGSA-N 0.000 title description 32
- 239000000651 prodrug Substances 0.000 title description 3
- 229940002612 prodrug Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 189
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 153
- 238000011282 treatment Methods 0.000 claims abstract description 118
- 201000010099 disease Diseases 0.000 claims abstract description 83
- 206010002022 amyloidosis Diseases 0.000 claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 78
- 208000035475 disorder Diseases 0.000 claims abstract description 70
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 40
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 30
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 29
- 230000009286 beneficial effect Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims description 64
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- -1 (tetrahydro-2H-pyran-4-yl)oxy Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 108010045517 Serum Amyloid P-Component Proteins 0.000 abstract description 121
- 102100036202 Serum amyloid P-component Human genes 0.000 abstract description 119
- KSKLDMGKWDUQCT-DNQXCXABSA-N oxan-4-yloxycarbonyloxymethyl (2R)-1-[6-[(2R)-2-(oxan-4-yloxycarbonyloxymethoxycarbonyl)pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound C(CCCCC(=O)N1[C@H](CCC1)C(=O)OCOC(=O)OC1CCOCC1)(=O)N1[C@H](CCC1)C(=O)OCOC(=O)OC1CCOCC1 KSKLDMGKWDUQCT-DNQXCXABSA-N 0.000 abstract description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
- 238000011260 co-administration Methods 0.000 description 36
- 208000037259 Amyloid Plaque Diseases 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 230000027455 binding Effects 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- 108010041986 DNA Vaccines Proteins 0.000 description 14
- 229940021995 DNA vaccine Drugs 0.000 description 14
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 108010094108 Amyloid Proteins 0.000 description 12
- 102000001049 Amyloid Human genes 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108010071690 Prealbumin Proteins 0.000 description 11
- 102000009190 Transthyretin Human genes 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 9
- 102100029290 Transthyretin Human genes 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 8
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 208000010544 human prion disease Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000003228 microsomal effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 7
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 7
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 7
- 206010064553 Dialysis amyloidosis Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 6
- 208000024777 Prion disease Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 6
- 208000014644 Brain disease Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 208000032274 Encephalopathy Diseases 0.000 description 5
- 241000772415 Neovison vison Species 0.000 description 5
- 241000282943 Odocoileus Species 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 230000003941 amyloidogenesis Effects 0.000 description 5
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 208000017580 chronic wasting disease Diseases 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 206010023497 kuru Diseases 0.000 description 5
- 210000001589 microsome Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- XRHUQJHOLVGXGQ-LIKPIUCQSA-N 1-(2,2-dimethylpropanoyloxy)ethyl (2r)-1-[6-[(2r)-2-[1-(2,2-dimethylpropanoyloxy)ethoxycarbonyl]pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CC(C)(C)C(=O)OC(C)OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OC(C)OC(=O)C(C)(C)C)CCC1 XRHUQJHOLVGXGQ-LIKPIUCQSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- ZYSHWMOCIONRRR-UHFFFAOYSA-N 3-butanoyl-7-methoxychromen-2-one Chemical compound C1=C(OC)C=C2OC(=O)C(C(=O)CCC)=CC2=C1 ZYSHWMOCIONRRR-UHFFFAOYSA-N 0.000 description 4
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 4
- GWMGUFTYUOYYQV-UHFFFAOYSA-N 7-methoxy-4-(methylaminomethyl)chromen-2-one Chemical compound C1=C(OC)C=CC2=C1OC(=O)C=C2CNC GWMGUFTYUOYYQV-UHFFFAOYSA-N 0.000 description 4
- SIDLHXXVIBTSJZ-UHFFFAOYSA-N 7-phenylmethoxyquinoline Chemical compound C=1C=C2C=CC=NC2=CC=1OCC1=CC=CC=C1 SIDLHXXVIBTSJZ-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 238000011238 DNA vaccination Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 150000001793 charged compounds Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000538 analytical sample Substances 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 230000000779 depleting effect Effects 0.000 description 3
- 230000008406 drug-drug interaction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- HZLAWYIBLZNRFZ-UHFFFAOYSA-N 1-[6-(2-carboxypyrrolidin-1-yl)-6-oxohexanoyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)CCCCC(=O)N1C(C(O)=O)CCC1 HZLAWYIBLZNRFZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010063045 Effusion Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010042938 Systemic candida Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- CVASMYWHWRNWOX-UHFFFAOYSA-N chloro methyl carbonate Chemical compound COC(=O)OCl CVASMYWHWRNWOX-UHFFFAOYSA-N 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- RAMYCVMRCSNXGX-UHFFFAOYSA-N chloromethyl oxan-4-yl carbonate Chemical compound ClCOC(=O)OC1CCOCC1 RAMYCVMRCSNXGX-UHFFFAOYSA-N 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000036732 invasive candidiasis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 2
- FBVVGPMIPAZFAW-DGPROHSZSA-N (2R)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1.OC(=O)[C@H]1CCCN1 FBVVGPMIPAZFAW-DGPROHSZSA-N 0.000 description 1
- KLEGMTRDCCDFJK-XDQSQZFTSA-N 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical group COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(O)(=S)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(S)(=O)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](CO)O[C@H]([C@@H]%10OCCOC)n%10cc(C)c(=O)[nH]c%10=O)O[C@H]([C@@H]9OCCOC)n9cc(C)c(N)nc9=O)O[C@H]([C@@H]8OCCOC)n8cc(C)c(=O)[nH]c8=O)O[C@H]([C@@H]7OCCOC)n7cc(C)c(=O)[nH]c7=O)O[C@H]([C@@H]6OCCOC)n6cnc7c6nc(N)[nH]c7=O)n6cnc7c6nc(N)[nH]c7=O)n6cc(C)c(=O)[nH]c6=O)n6cc(C)c(=O)[nH]c6=O)n6cnc7c(N)ncnc67)n6cc(C)c(N)nc6=O)n6cnc7c(N)ncnc67)n6cc(C)c(=O)[nH]c6=O)n6cnc7c6nc(N)[nH]c7=O)n6cnc7c(N)ncnc67)n6cnc7c(N)ncnc67)O[C@H]([C@@H]5OCCOC)n5cnc6c(N)ncnc56)O[C@H]([C@@H]4OCCOC)n4cc(C)c(=O)[nH]c4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(N)nc3=O)O[C@H]([C@@H]2OCCOC)n2cc(C)c(N)nc2=O)O[C@H]1n1cc(C)c(N)nc1=O KLEGMTRDCCDFJK-XDQSQZFTSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JZIMGKLVQCYNHJ-UHFFFAOYSA-N 2-[7-methoxy-2-oxo-4-(trifluoromethyl)chromen-3-yl]acetic acid Chemical compound FC(F)(F)C1=C(CC(O)=O)C(=O)OC2=CC(OC)=CC=C21 JZIMGKLVQCYNHJ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 101150019466 AOC1 gene Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000006171 Britton–Robinson buffer Substances 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 125000000180 D-prolyl group Chemical class N1[C@@H](C(=O)*)CCC1 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229910016860 FaSSIF Inorganic materials 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100498460 Mus musculus Dbnl gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KEHCYTSBTQQKRD-QZTJIDSGSA-N O=C(CCCCC(=O)N1[C@H](CCC1)C(=O)O)N1[C@H](CCC1)C(=O)OCOC(=O)OC1CCOCC1 Chemical compound O=C(CCCCC(=O)N1[C@H](CCC1)C(=O)O)N1[C@H](CCC1)C(=O)OCOC(=O)OC1CCOCC1 KEHCYTSBTQQKRD-QZTJIDSGSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000028361 Penetrating Head injury Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150036627 SAP gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000003396 anti-opsonic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229940045189 glucose-6-phosphate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000056262 human PPIG Human genes 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
- 230000007137 neurofibrillary pathology Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to the novel compound (2R,2'R)-Bis(((((tetrahydro-2H-pyran-4- yl)oxy)carbonyl)oxy)methyl) 1 ,1 '-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial.
- SAP serum amyloid P component
- Serum amyloid P component is a normal, structurally invariant, soluble, non-fibrillar, constitutive plasma glycoprotein, mass 127,310 Da, produced exclusively by the liver. It is composed of 5 identical 25,462 Da protomers non-covalently associated with cyclic pentameric symmetry in a disc like configuration. Each subunit, composed of a flattened ⁇ -jellyroll, with tightly tethered loops joining the ⁇ -strands, contains a single calcium dependent ligand binding site on the planar B (binding) face of the intact pentamer. SAP binds to all types of amyloid fibrils with the high avidity conferred by multivalent interactions.
- European patent application EP 0915088 discloses compounds which are competitive inhibitors of binding of SAP to amyloid fibrils, as well as methods for their manufacture.
- One of the compounds disclosed therein is (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo- hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC).
- amyloid fibrils About 25 different, unrelated, natively soluble, globular proteins form the amyloid fibrils which cause the different types of systemic amyloidosis but all amyloid fibrils have very similar morphology and the same cross- ⁇ core structure.
- This structure binds the ordered arrays of Congo red dye molecules which create pathognomonic red-green birefringence in strong cross polarised light: the gold standard diagnostic criterion for amyloid.
- Certain soluble, non-fibrillar plasma proteins may also be present in amyloid deposits but only one, serum amyloid P component (SAP), is universal in all human amyloid deposits, due to its avid, specific, calcium dependent binding to all types of amyloid fibrils.
- SAP serum amyloid P component
- Amyloid deposits disrupt the structure and function of affected tissues and organs, causing the serious disease, amyloidosis.
- Systemic amyloidosis is a rare, fatal condition caused by amyloid deposits which may be present in connective tissue and blood vessel walls throughout the body, as well as the parenchyma of the major organs, but never in brain substance itself.
- the amyloid deposits are confined to a single anatomical site or a single organ/tissue system.
- Cerebral amyloid angiopathy with amyloid deposition confined to the walls of cerebral blood vessels, is the most common and important form of local amyloidosis. It is responsible for a substantial proportion of intracerebral haemorrhages in both demented Alzheimer's disease patients and non- demented individuals, and is thus an important cause of dementia in its own right.
- Such antibodies could not be safely or effectively administered to patients with normal circulating concentrations of SAP since the antibodies would bind to the SAP in the plasma, forming tissue damaging immune complexes, and the antibodies would be consumed in this process making them unavailable for binding to SAP in amyloid.
- prior administration of CPHPC depletes SAP from the circulation, so that anti-SAP antibodies can be safely infused and remain available to bind to residual SAP left in the amyloid deposits. Binding of the antibodies to the amyloid-associated SAP activates the complement system and engages macrophages to phagocytose and destroy the amyloid deposits leading to clinical benefit.
- amyloid deposits are also present in two very common and important diseases: Alzheimer's disease and type 2 diabetes.
- the amyloid deposits are microscopic, are confined to the brain and islets of Langerhans respectively, and it is not known whether or how they may contribute to pathogenesis of neurodegeneration and diabetes respectively.
- Alzheimer's disease and type 2 diabetes thus cannot be classified as forms of amyloidosis but rather should be considered as amyloid associated diseases. Nevertheless, amyloid deposits are always present in them and the deposits also always contain SAP 15"19 .
- the brain in Alzheimer's disease also contains another type of abnormal insoluble fibrillar protein aggregate, known as neurofibrillary tangles, and SAP binds avidly to these, as it does to amyloid. 15"19 Neurofibrillary tangles bearing SAP, but not amyloid, are present in the brain in other types of dementia, including the frontotemporal dementias
- human SAP In addition to, and quite independent of, its role in amyloidosis, human SAP binds to and enters cerebral neurones and causes neuronal apoptosis in vitro and in v/Vo 9"13 . It has been shown that unique, pharmaceutical grade pure human SAP 14 disrupts synaptic transmission, causing abnormal paired pulse ratio and long term potentiation in organotypic rodent brain slices in vitro. The cerebral neurotoxicity of human SAP is therefore likely to contribute to neurodegeneration in humans 9"12, 20 . The fact that most of the common risk factors for dementia increase brain exposure to SAP is consistent with this concept.
- brain SAP Alzheimer's disease
- brain content of SAP is abnormally high due to its binding to amyloid deposits and neurofibrillary tangles 15"19 . This is also likely to be the case in other dementias with neurofibrillary tangles but not amyloid deposits.
- higher brain SAP content is reported in demented Alzheimer's disease patients than in elderly subjects who were cognitively intact at death, either with or without co-existing plaques and tangles at autopsy 20 .
- the significant positive correlation between cerebral SAP content and dementia 20 is consistent with a causative role for SAP.
- the quantities of SAP in cerebrospinal fluid and bound to cerebral amyloid deposits and neurofibrillary tangles are dramatically lower than in systemic extracellular fluid and on systemic amyloid deposits respectively.
- Depletion of plasma SAP by CPHPC from the normal 20-50 mg/L to ⁇ 0.1 mg/L, reduces the CSF SAP concentration from 2-30 ⁇ g L to ⁇ 0.1 ⁇ g L in patients with Alzheimer's disease 21 .
- Human SAP is produced only by the liver and reaches the brain via the blood 22 .
- CPHPC treatment thus removes virtually all SAP from the cerebrospinal fluid and, since SAP binding is fully reversible, will also remove it from the cerebral amyloid deposits and neurofibrillary tangles. Furthermore in Alzheimer's disease patients, CPHPC enters the cerebrospinal fluid 21 where it can also block binding of any free SAP to amyloid fibrils, to neurofibrillary tangles and cerebral neurones. All amyloid fibril types can be degraded by proteases and phagocytic cells in vitro and systemic amyloid deposits spontaneously regress slowly in vivo when the abundance of their respective fibril precursor proteins is sufficiently reduced 8 . Mechanisms for amyloid clearance thus do operate in vivo. Confirmation that human SAP is itself neurocytotoxic 9"13 , independent of its binding to amyloid, demonstrates the potential, additional, direct benefit of SAP depletion.
- SAP also binds avidly, in vivo as well as in vitro, to exposed DNA and chromatin, and to apoptotic cells. Increased cell death in osteoarthritic joints may thus provide ligands for SAP deposition.
- WO2004/108131 discloses the treatment of patients with osteoarthritis by injection of CPHPC ((R)-1 -[6-[(R)-2-carboxy-pyrrolidin-1 -yl]-6-oxo- hexanoyl]pyrrolidine-2-carboxylic acid) resulting in the alleviation of osteoarthritis symptoms.
- SAP Human SAP binds avidly to all forms of free DNA and also to chromatin, both in vitro and in vivo. Indeed SAP is the only normal human plasma protein which binds specifically in a calcium dependent interaction with DNA 23,24 . In contrast, SAP from some other species, including mouse and horse, binds weakly if at all to DNA, and dogs and rabbits do not even have the SAP gene and thus produce no SAP.
- DNA vaccination in which immunisation is achieved by injection of DNA coding for the immunogen rather by injection of the immunogen itself, has been extensively investigated as a highly desirable approach to induction of protective immunity against infections and as a potential immunotherapeutic intervention in cancer.
- SAP binds to some bacterial species but not to others.
- the SAP has a powerful anti-opsonic effect in vitro and in vivo, reducing phagocytosis and killing of the organisms and thus protecting them from the host's innate immune system 27 .
- This effect which promotes infectivity and virulence, is abrogated by administration of CPHPC to inhibit binding of SAP to the bacteria 27 .
- SAP is also present bound to the surface of the fungal cells in the tissues of patients suffering from invasive candidiasis 28 . This binding reflects the presence of amyloid fibrils, formed from fungal proteins, on the surface of the pathogenic organism.
- CPHPC is pharmacologically effective but it has very low and variable oral bioavailability of -3-5% and therefore only parenteral administration by intravenous infusion or subcutaneous injection is optimal to achieve the desired SAP depletion.
- most of the existing and potential indications for therapeutic SAP depletion require long term administration. Long term intravenous administration is not practical. Although long term subcutaneous administration is feasible, the injections may cause stinging discomfort and this is not tolerated by some patients. 7
- WO2003/051836 discloses D-prolines pro-drugs useful for the treatment of diseases where SAP depletion has a beneficial effect.
- the 25 Examples disclosed therein were predominantly obtained as oils; only 5 of them were solid.
- a divisional application to the European equivalent of WO2003/051836 was filed with claims directed to (R)-1-(6- ⁇ (R)-2-[1 -(2,2-dimethyl-propionyloxy)-ethoxycarbonyl]- pyrrolidin-1-yl ⁇ -6-oxo-hexanoyl)-pyrrolidine-2-carboxylic acid 1-(2,2-dimethyl-propionyloxy)- ethyl ester.
- GlaxoSmithKline group of companies has a Licence and Research Collaboration Agreement with Pentraxin Therapeutics Limited including a licence to EP 0915088 and WO2003/051836, and corresponding applications thereof.
- Pentraxin Therapeutics Limited including a licence to EP 0915088 and WO2003/051836, and corresponding applications thereof.
- the present invention provides a compound (2R,2'R)- bis((((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1 ,1 '-adipoylbis(pyrrolidine-2- carboxylate) according to Formula (I):
- the compound of Formula (I) is referred to hereinafter as "the compound of the invention".
- the compound of the invention exhibits good physiochemical properties and is capable of generating CPHPC in quantities capable of depleting SAP efficiently following oral administration.
- the compound of Formula (I) has good pH solution stability and intestinal microsome stability, and low liver microsome stability, readily generating CPHPC, suggesting the compound of Formula (I) will readily generate circulating levels of CPHPC on oral dosing in humans. Also, it does not show any interaction with cytochrome p450, suggesting the compound of Formula (I) will not show CYP450 mediated drug-drug interactions (DDIs). Additionally, the compound of Formula (I) is highly crystalline, which is advantageous with respect to formulation of the active substance and manufacture of the pharmaceutical product.
- the use of a compound with this profile may result in advantages in the treatment of diseases or disorders wherein depletion of SAP (serum amyloid P component) would be beneficial, for example in amyloidosis (including systemic amyloidosis and local amyloidosis), Alzheimer's disease, type II diabetes, osteoarthritis, bacterial infection, invasive candiasis and other fungal infections, and in conjunction with administration of DNA vaccines.
- the invention provides a pharmaceutical composition, which comprises a therapeutically effective amount of a compound of Formula (I) and optionally one or more pharmaceutically acceptable carriers and/or excipients.
- a compound of Formula (I) or one or more pharmaceutical compositions herein described for the depletion of circulating SAP in a subject is provided.
- kit of parts comprising one or more dosage forms of an anti-SAP antibody (in particular an antibody as disclosed in WO201 1/107480) and one or more dosage forms of the compound of Formula (I).
- an anti-SAP antibody in particular an antibody as disclosed in WO201 1/107480
- dosage forms of the compound of Formula (I) in particular an antibody as disclosed in WO201 1/107480
- “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal government of the United States of America or the corresponding agency in countries other than the United States of America (such as the EMA, the European Medicines Agency), or that is listed in the United States Pharmacopeia or European Pharmacopoeia (Ph. Eur.).
- “Therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease.
- antibody is used in the broadest sense to refer to molecules with an immunoglobulin-like domain and includes monoclonal, recombinant, polyclonal, chimeric, humanised, human, bispecific and heteroconjugate antibodies; and antigen binding fragments.
- An antibody according to the present invention activates the human complement system and/or results in regression of amyloid deposits.
- treatment includes acute treatment or prophylaxis as well as the alleviation of established symptoms and/or retardation of progression of the disease, and may include the suppression of symptom recurrence in an asymptomatic patient.
- anti-SAP in relation to an “antibody”, i.e. an “anti-SAP antibody”, means an antibody that binds to human SAP with no or insignificant binding to any other proteins, including closely related molecules such as C-reactive protein (CRP).
- CRP C-reactive protein
- CDR means complementarity determining region.
- a CDR of an antibody as used herein means a CDR as determined using any of the well known CDR numbering methods, including Kabat, Chothia, AbM and contact methods.
- circulating SAP is meant SAP that is present in free form in the plasma in vivo and in vitro and is not associated with amyloid deposits in the tissues.
- the invention therefore provides a pharmaceutical composition, which comprises a therapeutically effective amount of a compound of Formula (I) and optionally one or more pharmaceutically acceptable carriers and/or excipients.
- the present invention also provides a process for preparing a pharmaceutical composition, the process comprising admixing a therapeutically effective amount of a compound of Formula (I) and optionally one or more pharmaceutically acceptable carriers and/or excipients.
- the present invention also provides a dosage form comprising the pharmaceutical composition of the invention.
- a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, or lozenges.
- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); tabletting lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate).
- binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
- tabletting lubricants e.g. magnesium stearate, talc or silica
- disintegrants e.g. potato starch or sodium starch glycollate
- Oral liquid preparations may be in the form of, for example, oily suspension, non-aqueous solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with suitable aqueous or non-aqueous vehicle immediately prior to administration.
- Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g.
- the dosage form is a tablet or a capsule.
- the composition may contain from 0.1 % to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
- the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
- suitable unit doses may be 0.05 to 5000 mg, 1 .0 to 1000 mg, or 100 to 600 mg, for example 100, 200 or 300 mg, and such unit doses may be administered more than once a day, for example two or three times a day.
- Such therapy may extend for a number of days, weeks, months or years.
- the invention further provides the compound of Formula (I) or a pharmaceutical composition as herein described, as for use in therapy.
- the compound of Formula (I) is therefore of use in the treatment of diseases wherein SAP depletion would be beneficial.
- the invention further provides the compound of Formula (I) or a pharmaceutical composition as herein described, for use in depletion of SAP.
- a method of treatment of a disease or disorder in a subject wherein SAP depletion would be beneficial comprises administration of a therapeutically effective amount of the compound of Formula (I).
- a method of treatment of a disease or disorder in a subject wherein SAP depletion would be beneficial comprises administration of a therapeutically effective amount of a pharmaceutical composition as herein described.
- the invention further provides a method of depletion of SAP in a subject, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula (I).
- the invention further provides a method of depletion of SAP in a subject, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described.
- transmissible spongiform encephalopathy are associated with amyloid deposits in the brain, and the present invention therefore relates to all these diseases or disorders, including variant Creutzfeldt-Jakob disease in humans, Creutzfeldt- Jakob disease itself, kuru and the various other forms of human prion disease, and also bovine spongiform encephalopathy, chronic wasting disease of mule-deer and elk, and transmissible encephalopathy of mink.
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus, osteoarthritis, bacterial infections, invasive candiasis, transmissible spongiform encephalopathy, variant Creutzfeld-Jakob disease in humans, Creutzfeld-Jakob disease, kuru, other human prion diseases, bovine spongiform encephalopathy, chronic wasting disease of mule-deer and elk, and transmissible encephalopathy of mink, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula (I).
- the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus, osteoarthritis, bacterial infections, invasive candiasis, transmissible spongiform encephalopathy, variant Creutzfeld-Jakob
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus, osteoarthritis, bacterial infections, invasive candiasis, transmissible spongiform encephalopathy, variant Creutzfeld-Jakob disease in humans, Creutzfeld-Jakob disease, kuru, other human prion diseases, bovine spongiform encephalopathy, chronic wasting disease of mule-deer and elk, and transmissible encephalopathy of mink, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described.
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described.
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula (I).
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described.
- the invention further provides a method of treatment of a disease or disordwer in a subject, wherein the disease or disorder is amyloidosis, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula (I).
- the invention further provides a method of improvement of efficacy of human DNA vaccines, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula (I).
- the invention further provides a method of improvement of efficacy of human DNA vaccines, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described.
- the invention further provides the use of the compound of formula (I) in combination with a DNA vaccine.
- the invention further provides for the compound of Formula (I) for use in the improvement of the efficacy of human DNA vaccines.
- the invention further provides for a pharmaceutical composition as herein described for use in the improvement of the efficacy of human DNA vaccines.
- the invention further provides for the use of the compound of Formula (I) in the improvement of the efficacy of human DNA vaccines.
- the invention further provides for the use of a pharmaceutical composition as herein described in the improvement of the efficacy of human DNA vaccines.
- the invention further provides the use of the compound of Formula (I) in the manufacture of a medicament for use in the improvement of the efficacy of human DNA vaccines.
- improved in efficacy of human DNA vaccines is meant enabling the DNA vaccine to induce immunoprotective immune responses against the immunogens encoded by the human DNA vaccine.
- the subject may be a mammal.
- the subject is typically a human.
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of transmissible spongiform encephalopathy, variant Creutzfeldt-Jakob disease in humans, Creutzfeldt-Jakob disease, kuru, bovine spongiform encephalopathy, chronic wasting disease of mule-deer and elk, and transmissible encephalopathy of mink, which method comprises administering to the subject a therapeutically effective amount of the compound of Formula (I).
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting transmissible spongiform encephalopathy, variant Creutzfeldt-Jakob disease in humans, Creutzfeldt-Jakob disease, kuru , bovine spongiform encephalopathy, chronic wasting disease of mule-deer and elk, and transmissible encephalopathy of mink, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described.
- amyloidosis encompasses both systemic amyloidosis (including, but not limited to, AL-type amyloidosis, AA-type amyloidosis, dialysis amyloidosis, ATTR (transthyretin) amyloidosis, hereditary systemic amyloidosis) and local amyloidosis (including, but not limited to cerebral amyloid angiopathy).
- systemic amyloidosis including, but not limited to, AL-type amyloidosis, AA-type amyloidosis, dialysis amyloidosis, ATTR (transthyretin) amyloidosis, hereditary systemic amyloidosis
- local amyloidosis including, but not limited to cerebral amyloid angiopathy.
- the invention provides for the compound of Formula (I) or a pharmaceutical composition as herein described for use in the treatment of a disease or disorder wherein SAP depletion would be beneficial.
- the invention provides for the compound of Formula (I) or a pharmaceutical composition as herein described for use in the depletion of SAP. In one embodiment, the invention provides for the compound of Formula (I) or a pharmaceutical composition as herein described for use in the depletion of SAP in vivo.
- the invention provides for the compound of Formula (I) for use in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for a pharmaceutical composition as herein described for use in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the compound of Formula (I) for use in the treatment of a disease or disorder selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the compound of Formula (I) for use in the treatment of amyloidosis.
- the invention provides for a pharmaceutical composition as herein described for use in the treatment of a disease or disorder selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for a pharmaceutical composition as herein described for use in the treatment of amyloidosis.
- the invention provides for the use of a compound of Formula (I) or one or more pharmaceutical compositions herein described in the treatment of a disease or disorder wherein SAP depletion would be beneficial.
- the invention provides for the use of a compound of Formula (I) or one or more pharmaceutical compositions herein described in the depletion of SAP.
- the invention provides for the use of a compound of Formula (I) in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a compound of Formula (I) in the treatment of a disease or disorder selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a compound of Formula (I) in the treatment of amyloidosis.
- the invention provides for the use of a pharmaceutical composition herein described in the treatment of a disease or disorder selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a pharmaceutical composition herein described in the treatment of amyloidosis.
- the invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the treatment of a disease or disorder wherein SAP depletion would be beneficial.
- the invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the depletion of SAP.
- the invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the treatment of a disease or disorder selected from the group consisting of Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the treatment of amyloidosis.
- the compounds of Formula (I) may be administered with an anti-SAP antibody.
- the anti-SAP antibody binds to the A face of human SAP.
- the anti-SAP antibody comprises the heavy chain complementarity determining regions (CDRs) present within SEQ ID NO:28 and the light chain CDRs present within SEQ ID NO:35 in WO 1 1/107480.
- the anti-SAP antibody comprises a heavy chain variable region of SEQ ID NO:28 and a light chain variable region of SEQ ID NO:35 in WO 1 1/107480.
- the anti-SAP antibody comprises a human IgGI or lgG3 human constant domain.
- the anti-SAP antibody consists of a heavy chain of SEQ ID NO:62 and a light chain of SEQ ID NO:64 in WO 1 1/107480. Therefore, in a further aspect, the invention provides for a method of treatment of amyloidosis which method comprises administering to a subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody. In one embodiment, the administration of the compound of Formula (I) in co-administration with an anti-SAP antibody is sequential.
- the compound of Formula (I) is administered first.
- the anti-SAP antibody is administered when the level of circulating SAP in the subject has been reduced to a level of less than 2 mg/L. In one embodiment, the level of circulating SAP has been reduced to a level of 1 mg/L or less. In a further embodiment the level of circulating SAP has been reduced to a level of 0.5 mg/L or less.
- the level of circulating SAP can be measured using a commercially available ELISA (enzyme-linked immunosorbent assay) kit (e.g. HK331 Human SAP ELISA Kit from Hycult Biotech).
- ELISA enzyme-linked immunosorbent assay
- the compound of Formula (I) is administered for 5-8 days or until the level of the SAP circulating in the subject has been reduced to a level of less than 2 mg/L whichever is longer. In one embodiment, the level of the SAP circulating in the subject has been reduced to 1 mg/L or less. In a further embodiment, the level of SAP circulating in the subject has been reduced to 0.5 mg/L or less. In a further embodiment administration of the compound of Formula (I) is continued while a single dose of 200-2000 mg (preferably 250- 1000 mg, more preferably 250-600 mg) of anti-SAP antibody is administered, and for 4-6 days thereafter. This constitutes a 'therapeutic course' - patients may require several courses to achieve the desired therapeutic effect.
- the therapeutic course is repeated at least once at 3- 6 week intervals as required. In a further embodiment, the therapeutic course is repeated at least once at 3-6 week intervals followed by at least one therapeutic course at 6-12 month intervals as required.
- a method of treatment of a disease or disorder in a subject wherein SAP depletion would be beneficial comprises administration of a therapeutically effective amount of the compound of Formula (I) in co-administration with an anti-SAP antibody.
- a method of treatment of a disease or disorder in a subject wherein SAP depletion would be beneficial comprises administration of a therapeutically effective amount of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody.
- a method of depletion of SAP comprises administration of a therapeutically effective amount of the compound of Formula (I) in coadministration with an anti-SAP antibody.
- a method of depletion of SAP which method comprises administration of a therapeutically effective amount of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody.
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis, which method comprises administering to the subject a therapeutically effective amount of a compound of Formula (I) in co-administration with an anti-SAP antibody.
- the invention further provides a method of treatment of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis, which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody.
- the invention provides for the compound of Formula (I) or one or more pharmaceutical compositions herein described in co-administration with an anti-SAP antibody for use in the treatment of a disease or disorder wherein SAP depletion would be beneficial.
- the invention provides for the compound of Formula (I) or one or more pharmaceutical compositions herein described in co-administration with an anti-SAP antibody for use in the depletion of SAP.
- the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of amyloidosis.
- the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of systemic amyloidosis.
- the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of AL-type amyloidosis.
- the invention provides for the compound of Formula (I) in co- administration with an anti-SAP antibody for use in the treatment of AA-type amyloidosis.
- the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of dialysis amyloidosis. In one embodiment, the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of ATTR (transthyretin) amyloidosis.
- the invention provides for the compound of Formula (I) in co- administration with an anti-SAP antibody for use in the treatment of hereditary systemic amyloidosis.
- the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of local amyloidosis. In one embodiment, the invention provides for the compound of Formula (I) in coadministration with an anti-SAP antibody for use in the treatment of cerebral amyloid angiopathy.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of amyloidosis.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of systemic amyloidosis.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of AL-type amyloidosis.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of AA-type amyloidosis. In one embodiment, the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of dialysis amyloidosis.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of ATTR (transthyretin) amyloidosis.
- the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of hereditary systemic amyloidosis. In one embodiment, the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of local amyloidosis. In one embodiment, the invention provides for a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the treatment of cerebral amyloid angiopathy.
- the invention provides for the use of a compound of Formula (I) or a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of a disease or disorder wherein SAP depletion would be beneficial.
- the invention provides for the use of a compound of Formula (I) or a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody for use in the depletion of SAP.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of amyloidosis.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of systemic amyloidosis. In one embodiment, the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of AL-type amyloidosis.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of AA-type amyloidosis.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of dialysis amyloidosis. In one embodiment, the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of ATTR (transthyretin) amyloidosis.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of hereditary systemic amyloidosis.
- the invention provides for the use of a compound of Formula (I) in co- administration with an anti-SAP antibody in the treatment of local amyloidosis.
- the invention provides for the use of a compound of Formula (I) in coadministration with an anti-SAP antibody in the treatment of cerebral amyloid angiopathy.
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of amyloidosis. In one embodiment, the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of systemic amyloidosis.
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of AL-type amyloidosis.
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of AA-type amyloidosis. In one embodiment, the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of dialysis amyloidosis. In one embodiment, the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of ATTR (transthyretin) amyloidosis.
- ATTR transthyretin
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of hereditary systemic amyloidosis.
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of local amyloidosis.
- the invention provides for the use of a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody in the treatment of cerebral amyloid angiopathy.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of a disease or disorder wherein SAP depletion would be beneficial.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the depletion of SAP.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of a disease or disorder selected from the group consisting of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of systemic amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of AL-type amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of AA-type amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of dialysis amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of ATTR (transthyretin) amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of hereditary systemic amyloidosis. In one embodiment, the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of local amyloidosis.
- the invention provides for the use of a compound of Formula (I) and an anti-SAP antibody in the manufacture of a medicament for use in the treatment of cerebral amyloid angiopathy.
- the disease or disorder is amyloidosis. In a further embodiment the disease or disorder is systemic amyloidosis.
- the disease or disorder is AL-type amyloidosis. In a further embodiment the disease or disorder is AA-type amyloidosis. In a further embodiment the disease or disorder is dialysis amyloidosis.
- the disease or disorder is ATTR (transthyretin) amyloidosis.
- the disease or disorder is hereditary systemic amyloidosis.
- the disease or disorder is local amyloidosis.
- the disease or disorder is cerebral amyloid angiopathy. In one embodiment the disease or disorder is Alzheimer's disease.
- the disease or disorder is type 2 diabetes mellitus.
- the disease or disorder is osteoarthritis.
- an article of manufacture, or "kit of parts” containing one or more unit doses of an anti-SAP antibody and one or more unit doses of the compound of Formula (I), useful for the treatment of amyloidosis, is provided.
- kit of parts comprises a unit dose of an anti-SAP antibody and one or more unit doses of the compound of Formula (I).
- the kit of parts is formulated for the separate or sequential administration of the one or more unit doses of compound of Formula (I) and the unit dose of the anti-SAP antibody.
- the kit of parts comprises a container comprising one or more unit doses of the compound of Formula (I) or a pharmaceutical composition as herein described and the unit dose of the anti-SAP antibody.
- the kit of parts comprises a first container comprising one or more unit doses of the compound of Formula (I) or a pharmaceutical composition as herein described and a second container comprising the unit dose of the anti-SAP antibody.
- the kit of parts may further comprise directions for the administration of the one or more unit doses of compound of Formula (I) and the unit dose of the anti-SAP antibody for treating or preventing amyloidosis.
- an article of manufacture, or "kit of parts" containing one or more unit doses of the compound of Formula (I) or a pharmaceutical composition as herein described and one or more unit doses of a DNA vaccine is provided.
- Suitable containers include, for example, bottles, vials, syringes and blister packs, etc.
- WO201 1/139917 discloses anti-transthyretin (anti-TTR) antisense oligonucleotides potentially useful in the modulation of expression of transthyretin and in treating, preventing, delaying or ameliorating transthyretin amyloidosis.
- the invention provides for a method of treatment of ATTR (transthyretin) amyloidosis, which method comprises i) administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody, and ii) administering to a subject a therapeutically effective amount of an anti-TTR antisense oligonucleotide.
- the anti-TTR antisense oligonucleotide is ISIS 420915.
- steps i) and ii) are carried out sequentially. In one embodiment, step ii) is carried out after step i).
- WO2009040405 discloses agents for stabilising the tetrameric form of transthyretin useful in the treatment or prevention of transthyretin amyloidosis. Therefore, in another aspect, the invention provides for a method of treatment of ATTR (transthyretin) amyloidosis, which method comprises i) administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition as herein described in co-administration with an anti-SAP antibody, and ii) administering to a subject a therapeutically effective amount of an agent as described in WO2009040405.
- steps i) and ii) are carried out sequentially. In one embodiment, step ii) is carried out after step i).
- the compound of Formula (I) may be synthesised substantially according to Reaction Scheme 1.
- the compounds of Formula (I) can be prepared by reaction of the chloromethyl carbonate of Formula (II) with CPHPC in the presence of a solvent (e.g. dioxane), a base (e.g. potassium carbonate) and catalytic amounts of TBAI (tetrabutylammonium iodide).
- a solvent e.g. dioxane
- a base e.g. potassium carbonate
- TBAI tetrabutylammonium iodide
- the chloromethyl carbonate of Formula (II) can be prepared by reaction of chloromethyl carbonochloridate with tetrahydro-2H-pyran-4-ol in the presence of a solvent (e.g. diethyl ether or dichloromethane) and a base (e.g. pyridine or dimethylaminopyridine).
- a solvent e.g. diethyl ether or dichloromethane
- a base e.g. pyridine or dimethylaminopyridine.
- Chloromethyl carbonochloridate also known as chloromethyl chloroformate
- tetrahydro- 2H-pyran-4-ol are commercially available (Aldrich).
- the compounds of Formula (I) can be synthesised substantially according to Reaction Scheme 2 starting from D-proline ((R)-pyrrolidine-2-carboxylic acid).
- the compound in the box is CPHPC.
- D-proline is commercially available (Aldrich).
- Example illustrates the invention. This Example is not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compound, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the invention. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth. The following Intermediates and Examples illustrate the preparation of the compound of the invention.
- Vr 2 0 isopropyl ether
- HPLC was conducted on a Waters X-Terra MS C18 column (3.5 ⁇ 30 x 4.6 mm id) eluting with 0.01 M ammonium acetate in water (solvent A) and 100% acetonitrile (solvent B), using the following elution gradient 0-0.5 minutes 5% B, 0.5- 3.75 minutes 5% to 100% B, 3.75-4.5 100% B, 4.5-5 100% to 5% B, 5-5.5 5% B at a flow rate of 1.3 ml/minute at 40°C.
- MS mass spectra
- Analytical HPLC was conducted on a XSelect XP C18 column (2.5 ⁇ 30 x 4.6 mm id) eluting with 0.1 % formic acid in water (solvent A) and 0.1 % formic acid in acetonitrile (solvent B), using the following elution gradient 0-3.2 minutes: 5% to 100% B, 3.2-4.0 minutes 100% B, at a flow rate of 1.8 ml/minute at 40°C.
- MS mass spectra
- Solution A Potassium carbonate (29.8 g, 216 mmol) was added to a stirred suspension of (2R,2'R)-1 ,1 '-adipoylbis(pyrrolidine-2-carboxylic acid) (35 g, 103 mmol) in 1 ,4-dioxane (1 L) and the reaction mixture was stirred at 80°C for 30 min.
- Solution B TBAI (7.60 g, 20.57 mmol) was added to a solution of chloromethyl (tetrahydro- 2H-pyran-4-yl) carbonate (42.0 g, 216 mmol) in dioxane (50 mL) and the mixture was stirred at RT for 15 min.
- the solution B was added to the solution A.
- the reaction mixture was stirred at 80°C for 18 h.
- the reaction mixture was filtered and concentrated under reduced pressure. The residue was taken up in EtOAc (400 mL) and washed with an aq. solution of NaHC0 3 (2 x 100 mL), an aq. solution of sodium thiosulfate (50 mL) and with 0.5N HCI (100 mL). The organic layer was dried over anhydrous Na 2 S0 4 , filtered and concentrated in vacuo. The yellow oil was solubilized in 2-MeTHF(100 mL) and sonicated until crystallization occurred. The mixture was left to stand for 1 h at RT.
- XRPD data were acquired on a PANalytical X'Pert Pro powder diffractometer, model PW3040/60 using an X'Celerator detector.
- the acquisition conditions were: radiation: Cu Ka, generator tension: 40 kV, generator current: 45 mA, start angle: 2.0° 2 ⁇ , end angle: 40.0° 2 ⁇ , step size: 0.0167° 2 ⁇ , time per step: 31 .75 seconds.
- the sample was prepared by mounting a few milligrams of sample (compound of Formula (I)) on a silicon wafer (zero background plate), resulting in a thin layer of powder.
- Characteristic XRPD angles and d-spacings for the compound of Formula (I) are recorded in Table 1.
- the margin of error is approximately ⁇ 0.1 ° 2 ⁇ for each of the peak assignments. Peak intensities may vary from sample to sample due to preferred orientation.
- Table 1 XRPD diffraction angles and d-spacings for compound of Formula (I)
- the invention provides for a compound of Formula (I) in crystalline form.
- the invention provides for a compound of Formula (I) as a crystalline solid characterised by an XRPD spectrum that is substantially as shown in Figure 1.
- the invention provides for a compound of Formula (I) as a crystalline solid characterised by an XRPD spectrum comprising the peaks of Table 1.
- (2R,2'R)-bis(1-(pivaloyloxy)ethyl) 1 ,1 '-adipoylbis(pyrrolidine-2-carboxylate) also known as (R)-1 -(6- ⁇ (R)-2-[1 -(2,2-dimethyl-propionyloxy)-ethoxycarbonyl]-pyrrolidin-1 -yl ⁇ -6-oxo- hexanoyl)-pyrrolidine-2-carboxylic acid 1 -(2,2-dimethyl-propionyloxy)-ethyl ester
- (R)-1 -(6- ⁇ (R)-2-[1 -(2,2-dimethyl-propionyloxy)-ethoxycarbonyl]-pyrrolidin-1 -yl ⁇ -6-oxo- hexanoyl)-pyrrolidine-2-carboxylic acid 1 -(2,2-dimethyl-propionyloxy)-ethyl ester)
- the compound of Formula (I) is obtainable as a crystalline solid.
- Comparator Compound is obtained as an oil (see WO2003/051836). Solubility
- a known quantity of the compound of Formula (I) was weighed into a suitable vessel (e.g. a screw capped clear glass vial) and a known volume of the required media added (e.g. Simulated Gastric Fluid pH 1.6[SGF], Simulated Fed State Intestinal Fluid pH 6.5 [FeSSIF], Simulated Fasted State Intestinal Fluid pH 6.5 [FaSSI F], Water [Purified Water], or Britton- Robinson buffer).
- the compound was wetted with the media by vortex mixing for 30 seconds to 1 minute.
- the sample was then visually observed to ensure that undissolved solid remained present.
- the sample was transferred to a gentle mixer (such as a roller mixer) and allowed to agitate until the desired time point was reached.
- the solubility of the compound can then be calculated using a knowledge of the concentration of the standard, the relative response (e.g. peak areas) of the standard and the analytical sample described, and the dilution of the analytical sample.
- the assay was designed to evaluate inhibition on cytochrome P450 (CYP) 3A4, 2C9, 2C19, 1A2 and 2D6 enzymes from bactosomes source using fluorogenic substrates.
- Compound Compound of Formula (I) or Comparator Compound
- CYP cytochrome P450
- Compound of Formula (I) or Comparator Compound was dissolved in methanol at 1.65mM.
- Daughter solutions were prepared in methanol at 660, 264, 106, 42, 17, 6.8, 2.7, 1.1 and 0.43 ⁇ .
- NADPH cofactor was prepared with Glucose-6-phosphate (7.8mg), Glucose -6- phosphate dehydrogenase (6 units), NADP (1 .7mg) per 1 ml_ in NaHC0 3 2%.
- Substrate preparation was as follows:
- DiEthoxyFluorescein (DEF) : 0.1 mM in acetonitrile Bactosomes (Cypex source) at the concentration of 10mg of protein per ml were diluted in phosphate buffer 50mM pH7.4:
- Pre-lncubation consisted in mixing 5 ⁇ of compound solution with 220 ⁇ diluted bactosomes and warming it at 37°C for 10min. Incubation was started with the addition of 25 ⁇ of NADPH. Then fluorescence of substrate metabolite was read in a SAFIRE instrument (from Tecan) for 5 min :
- Table 3 Inhibition of cytochrome p450 enzymes by compound of Formula (I) (Example 1 ) and Comparator Compound.
- CYP3A4 inhibition is relevant as only intestinal inhibition will be relevant (CYP3A is present in enterocytes and is responsible for enterocyte first pass).
- Protocol for determining physical stability The assay was designed for determining physical stability of compound in buffer at various pHs.
- Compound of Formula (I) was dissolved in DMSO at 1 mg/ml.
- Phosphate buffer (PBS) was prepared by mixing K 2 HP0 4 50mM and KH 2 P0 4 50mM solutions to obtain 4 buffers at pH 6.0, 7.0, 7.5, 8.0.
- Figure 2 In vitro physical hydrolysis of compound of Formula (I) in phosphate buffered saline at pH6, 7, 7.5 and 8
- monoester of CPHPC is meant the compound (R)-1-(6-oxo-6-((R)-2-((((((tetrahydro-2H- pyran-4-yl)oxy)carbonyl)oxy)methoxy)carbonyl)pyrrolidin-1 -yl)hexanoyl)pyrrolidine-2- carboxylic acid of Formula (III).
- the assay was designed for determining stability of compound in microsomal matrix.
- Compound Compound of Formula (I)
- Daughter solution was prepared in methanol/water (50/50) at 30.3ng/ml.
- Microsomes (from Xenotech) were diluted at 0.625mg proteins per ml in phosphate buffer 50mM pH 7.4.
- Pre-lncubation consisted of warming microsomal solution 395 ⁇ with 100 ⁇ NaHC0 3 (2%) at 37°C for 7min. Incubation was started with the addition of 5 ⁇ of daughter solution. 50 ⁇ aliquots of mixture were taken at 0, 3, 6, 12 and 30min and quenched with 150 ⁇ acetonitrile containing internal standard.
- Controls were made to calculate percentage of disappearance of parent but also appearance of suspected metabolite, i.e. monoester and diacidic form.
- Figure 3 In vitro Intestinal Microsomal Stability of Compound of Formula (I) in human microsomes. "0/5/10/30/60min” refers to the time (in minutes) that the sample was taken from the mixture for analysis.
- the compound of Formula (I) is transported through the intestinal wall and is transported to the bloodstream and liver, both sites of circulating SAP.
- the assay was designed for determining stability of compound in fresh blood.
- Compound (compound of Formula (I)) was dissolved in DMSO at 1 mg/ml.
- Daughter solution was prepared in DMSO at 100 ⁇ g/ml.
- Fresh blood was diluted 1 ⁇ 2 in isotonic buffer pH 7.4.
- Pre-lncubation consisted of warming 792 ⁇ of blood at 37°C for 7 min. Incubations were started with the addition of 5 ⁇ of daughter solution. 50 ⁇ of mixture were taken at 0, 5, 15, 30 and 60min. 50 ⁇ of water was add to sample and then quenched with 300 ⁇ acetonitrile containing internal standard.
- Figure 4 In vitro Blood stability of compound of Formula (I) in human blood. "0/5/10/30/60 min” refers to the time (in minutes) that the sample was taken from the mixture for analysis. In vitro liver microsomal activity of was assessed using the protocol detailed above (Intestine and Liver Microsomal Assay protocol).
- Figure 5 In vitro Liver microsomal stability of compound of Formula (I) in human liver microsomes. "0/5/10/30/60min” refers to the time (in minutes) that the sample was taken from the mixture for analysis.
- Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA, 92: 4299-4303.
- Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med., 3: 855-859. 3. Hamazaki, H. (1995) Amyloid P component promotes aggregation of Alzheimer's ⁇ -amyloid peptide. Biochem. Biophys. Res. Commun., 211: 349-353.
- Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration. Brain Res., 1145: 221-226.
- Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem. Biophys. Res. Commun., 148: 308- 313.
- Serum amyloid P component facilitates DNA clearance and inhibits plasmid transfection: implications for human DNA vaccine. Gene Ther.: [Epub ahead of print].
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167029703A KR20160145617A (ko) | 2014-04-29 | 2015-04-27 | 1,1''-(1,6-디옥소-1,6-헥산디일)비스-d-프롤린의 프로드럭 |
JP2016565212A JP6445046B2 (ja) | 2014-04-29 | 2015-04-27 | 1,1’−(1,6−ジオキソ−1,6−ヘキサンジイル)ビス−d−プロリンのプロドラッグ |
EP15720312.6A EP3137457B1 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
SG11201608371RA SG11201608371RA (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
CN201580023347.0A CN106459016B (zh) | 2014-04-29 | 2015-04-27 | 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药 |
UAA201612105A UA119871C2 (uk) | 2014-04-29 | 2015-04-27 | Проліки 1,1'-(1,6-діоксо-1,6-гександіїл)біс-d-проліну |
CR20160508A CR20160508A (es) | 2014-04-29 | 2015-04-27 | Un profármaco de 1,1´-(1,6-dioxo-1,6-hexanodiilo)bis-d-prolina |
MA39406A MA39406B1 (fr) | 2014-04-29 | 2015-04-27 | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
MX2016014246A MX2016014246A (es) | 2014-04-29 | 2015-04-27 | Un profarmaco de 1,1'-(1,6-dioxo-1,6-hexanediil)bis-d-prolina. |
ES15720312T ES2731253T3 (es) | 2014-04-29 | 2015-04-27 | Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanodiil)bis-d-prolina |
EA201692185A EA032129B1 (ru) | 2014-04-29 | 2015-04-27 | Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина |
AU2015252184A AU2015252184B2 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
CA2947060A CA2947060C (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
US14/787,608 US9701668B2 (en) | 2014-04-29 | 2015-04-27 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
BR112016025129A BR112016025129A2 (pt) | 2014-04-29 | 2015-04-27 | novo composto |
MYPI2016703952A MY191088A (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
US14/925,350 US9737505B2 (en) | 2014-04-29 | 2015-10-28 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
IL248249A IL248249A0 (en) | 2014-04-29 | 2016-10-09 | 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline prodrug |
PH12016502006A PH12016502006B1 (en) | 2014-04-29 | 2016-10-10 | A prodrug of 1,1`-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
US15/610,984 US9873686B2 (en) | 2014-04-29 | 2017-06-01 | Prodrug of 1,1′-(1,6-dioxo -1,6-hexanediyl)bis-D-proline |
US15/837,297 US10597385B2 (en) | 2014-04-29 | 2017-12-11 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
IL279120A IL279120A (en) | 2014-04-29 | 2020-12-01 | 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline prodrug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
GB1407506.3 | 2014-04-29 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/787,608 A-371-Of-International US9701668B2 (en) | 2014-04-29 | 2015-04-27 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
US14/925,350 Continuation-In-Part US9737505B2 (en) | 2014-04-29 | 2015-10-28 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
US15/610,984 Continuation US9873686B2 (en) | 2014-04-29 | 2017-06-01 | Prodrug of 1,1′-(1,6-dioxo -1,6-hexanediyl)bis-D-proline |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015165833A1 true WO2015165833A1 (en) | 2015-11-05 |
Family
ID=50972033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/058998 WO2015165833A1 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Country Status (26)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017072099A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | D-proline derivatives as sap depleting agent |
WO2024052693A1 (en) | 2022-09-08 | 2024-03-14 | Cambridge Enterprise Limited | Prodrugs |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051836A1 (en) * | 2001-12-14 | 2003-06-26 | F. Hoffmann-La Roche Ag | Prodrugs to d-prolines |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE224366T1 (de) | 1997-10-31 | 2002-10-15 | Hoffmann La Roche | D-prolinderivate |
BRPI0410936A (pt) | 2003-06-05 | 2006-06-27 | Pfizer Prod Inc | pró-fármaco inibidor da beta-lactamase |
GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
CA2604206A1 (en) | 2005-04-12 | 2006-10-19 | Meiji Seika Kaisha, Ltd. | 2-thioethenyl substituted carbapenem derivatives |
GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 CA CA2947060A patent/CA2947060C/en active Active
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/en active Active
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Application Discontinuation
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/en active Application Filing
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja active Active
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en active Active
- 2015-04-27 US US14/787,608 patent/US9701668B2/en active Active
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en active Active
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051836A1 (en) * | 2001-12-14 | 2003-06-26 | F. Hoffmann-La Roche Ag | Prodrugs to d-prolines |
Non-Patent Citations (1)
Title |
---|
AESOP CHO: "Recent Advances in Oral Prodrug Discovery", ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 41, 2006, Elsevier Inc, pages 395 - 407, XP009184520, ISSN: 0065-7743 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017072099A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | D-proline derivatives as sap depleting agent |
US10328052B2 (en) | 2015-10-27 | 2019-06-25 | Glaxosmithkline Intellectual Property Development Limited | D-proline derivatives as SAP depleting agent |
WO2024052693A1 (en) | 2022-09-08 | 2024-03-14 | Cambridge Enterprise Limited | Prodrugs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10597385B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
JP2008179541A (ja) | 神経因性疼痛治療薬 | |
US20240217922A1 (en) | Modulators of sortilin activity | |
US9737505B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
EP3368532B1 (en) | D-proline derivative as sap depleting agent | |
EA017968B1 (ru) | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
US20240002371A1 (en) | Phthalazine derivatives as p2x3 inhibitors | |
CN113825542A (zh) | 精氨酸牙龈蛋白酶抑制剂 | |
EP4178945B1 (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
US20240150315A1 (en) | Beta-2 adrenoreceptor modulators and methods of using same | |
WO2023165459A1 (en) | Compounds as sars-cov-2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 14787608 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15720312 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001934-2016 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 248249 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12016502006 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 20167029703 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2947060 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 39406 Country of ref document: MA |
|
ENP | Entry into the national phase |
Ref document number: 2015252184 Country of ref document: AU Date of ref document: 20150427 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016565212 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2016/0003520 Country of ref document: CO Ref document number: CR2016-000508 Country of ref document: CR Ref document number: MX/A/2016/014246 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016025129 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2015720312 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015720312 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201692185 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201612105 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 112016025129 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161027 |